CONTRAST
ENHANCED COMPUTED TOMOGRAPHY USING INTRAVENOUS IODINE IN PATIENTS WITH THYROID CANCER-IS
IT A PROBLEM?
When computed
tomography is indicated in patients with thyroid cancer, use of intravenous iodine
contrast is an important adjunct because it helps to delineate clearly the anatomic
relationship between the primary tumor or metastatic disease (foci) and
adjacent structures. There is a concern about iodine burden from intravenous
contrast causing a clinically significant delay in subsequent whole-body scans
or radioiodine ablation therapy after the imaging followed by surgery. However,
this concern is unfounded since iodine is generally cleared within 4-8 weeks in
most patients. In general, the benefit from improved anatomic imaging outweighs
any potential risk of a short (some weeks) delay in radioiodine imaging or
radioiodine ablation therapy.
ATA
ΒΙΟΓΡΑΦΙΚΟ
ΕΠΙΚΟΙΝΩΝΙΑ
ΓΙΑΤΙ ΕΜΑΣ?
ΚΟΣΤΟΣ - ΔΙΑΔΙΚΑΣΙΑ
VIDEOS
ΑΡΘΡΑ
ΠΑΘΗΣΕΙΣ ΘΥΡΕΟΕΙΔΟΥΣ
ΠΑΘΗΣΕΙΣ ΠΑΡΑΘΥΡΕΟΕΙΔΩΝ
ΜΑΡΤΥΡΙΕΣ ΑΣΘΕΝΩΝ
Σχόλια
Δημοσίευση σχολίου